Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
03 août 2023 08h00 HE
|
Compass Therapeutics
Continuing to enroll patients in a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected in the...
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
22 juin 2023 16h05 HE
|
Compass Therapeutics
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics to Participate in Upcoming Investor Events
01 juin 2023 10h06 HE
|
Compass Therapeutics
BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
04 mai 2023 08h30 HE
|
Compass Therapeutics
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half...
Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
26 avr. 2023 08h30 HE
|
Compass Therapeutics
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
19 avr. 2023 08h30 HE
|
Compass Therapeutics
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium
28 mars 2023 08h30 HE
|
Compass Therapeutics
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
15 mars 2023 08h30 HE
|
Compass Therapeutics
Initiated U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC); initial results are expected in the first half of 2024 Initiated...
Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference
02 févr. 2023 08h30 HE
|
Compass Therapeutics
BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
19 janv. 2023 17h00 HE
|
Compass Therapeutics
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the...